AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21345843 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (TAT, DAT plus cilostazol)
Number of subjects: 474
Study 21345843 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (TAT) in carriers of CYP2C19 LOF allele
Number of subjects: 474
Study 21345843 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAT) in carriers of CYP2C19 LOF allele
Number of subjects: 474
Study 21345843 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAT) in non-carriers of CYP2C19 LOF allele
Number of subjects: 474
Study 18197184 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE)
Number of subjects: 45
Study 18197184 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-State Exercise (SSE)
Number of subjects: 45
Study 18197184 — intervention group
Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 45
Study 16484290 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost treatment (intravenous infusion at progressively increasing doses from 0.5 to 2 ng/kg/min for 6 hours each day for 10 days, repeated every 3 months for 18 months)
Number of subjects: 30
Study 16484290 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost treatment (new protocol)
Number of subjects: 30
Study 16484290 — intervention group
Group type: COMPARATOR
Intervention: Iloprost treatment (different dosing schemes)
Number of subjects: 30
Study 12930167 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.3 g.kg body mass per day for 6 days)
Number of subjects: 15
Study 12930167 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 15
Study 10735426 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam irradiation (7 Gy at 0-24 hours and 24-48 hours after intervention)
Number of subjects: 31
Study 10735426 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty and/or stent placement alone (control group)
Number of subjects: 31
Study 8884833 — intervention group
Group type: EXPERIMENTAL
Intervention: Hanks balanced salt solution
Number of subjects: 0
Study 8884833 — intervention group
Group type: EXPERIMENTAL
Intervention: Custodiol solution
Number of subjects: 0
Study 8884833 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline solution
Number of subjects: 0
Study 1326734 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose 4'-epi-doxorubicin + cyclophosphamide (800 mg/m2)
Number of subjects: 111
Study 1326734 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose 4'-epi-doxorubicin + cisplatin (60 mg/m2)
Number of subjects: 111
Study 3915883 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg once daily for 15 days
Number of subjects: 100
Study 3915883 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg once daily for 15 days
Number of subjects: 100
Study 31820603 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Qianlianquan (Extra) and eight confluent points (Neiguan (PC 6), Waiguan (TE 5), Lieque (LU 7), Houxi (SI 3), Gongsun (SP 4), Shenmai (BL 62), Zhaohai (KI 6), Zulinqi (GB 41)), once a day, 6 days as one course, 4 courses total
Number of subjects: 42
Study 31820603 — intervention group
Group type: COMPARATOR
Intervention: Qinghou Liyan granules, 5 g each time, 3 times a day, 7 days as one course, 4 courses total
Number of subjects: 42
Study 30361170 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 945
Study 30361170 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 945
Study 30361170 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 945
Study 26945407 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour infusion of recombinant human atrial natriuretic peptide (rhANP)
Number of subjects: 477
Study 26945407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study 24091995 — intervention group
Group type: EXPERIMENTAL
Intervention: Overload training (n = 18)
Number of subjects: 27
Study 24091995 — intervention group
Group type: COMPARATOR
Intervention: Control training (CTL, n = 9)
Number of subjects: 27
Study 24091995 — intervention group
Group type: EXPERIMENTAL
Intervention: Overload training (F-OR, n = 9)
Number of subjects: 27
Study 24091995 — intervention group
Group type: EXPERIMENTAL
Intervention: Overload training (AF, n = 9)
Number of subjects: 27
Study 22197455 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus-based juice (300 mL daily for 6 months)
Number of subjects: 33
Study 22197455 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (300 mL daily for 6 months)
Number of subjects: 33
Study 20711715 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump treatment with continuous glucose monitoring
Number of subjects: 160
Study 20711715 — intervention group
Group type: COMPARATOR
Intervention: Conventional self‐monitoring blood glucose measurements (Control)
Number of subjects: 160
Study 20711715 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-treated 12‐ to 16‐year‐old patients
Number of subjects: 160
Study 20711715 — intervention group
Group type: COMPARATOR
Intervention: Control group without sensors
Number of subjects: 160
Study 17543505 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (n=120)
Number of subjects: 235
Study 17543505 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (n=115)
Number of subjects: 235
Study 15199625 — intervention group
Group type: EXPERIMENTAL
Intervention: Jieyu pill (JYP)
Number of subjects: 57
Study 15199625 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline (Map)
Number of subjects: 57
Study 12173815 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukodepletion (group B: n = 20)
Number of subjects: 40
Study 12173815 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile CPB without leukodepletion (group A: n = 20)
Number of subjects: 40
Study 9814931 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy density shock wave therapy (1500 impulses of 0.06 mJ/mm2)
Number of subjects: 100
Study 9814931 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy density shock wave therapy (1500 impulses of 0.28 mJ/mm2)
Number of subjects: 100
Study 9027784 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis with cuprophane membranes
Number of subjects: 20
Study 9027784 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis with polysulphone membranes
Number of subjects: 20
Study 9027784 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis patients
Number of subjects: 20
Study 9027784 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis
Number of subjects: 20
Study 9027784 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 1843987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric sulfate (FS)
Number of subjects: 62
Study 1843987 — intervention group
Group type: COMPARATOR
Intervention: Formocresol (FC)
Number of subjects: 62
Study 6177167 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 0.025% (Preferid)
Number of subjects: 9
Study 6177167 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone‐17‐butyrate 0.1% (Locoid)
Number of subjects: 9
Study 6177167 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone‐17,21‐dipropionate 0.5% (Diproderm)
Number of subjects: 9
Study 31352497 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted total knee arthroplasty (rTKA)
Number of subjects: 10
Study 31352497 — intervention group
Group type: COMPARATOR
Intervention: Conventional measured resection total knee arthroplasty (sTKA)
Number of subjects: 10
Study 31352497 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rTKA and sTKA
Number of subjects: 10
Study 30611296 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant salpingectomy
Number of subjects: 2800
Study 30611296 — intervention group
Group type: COMPARATOR
Intervention: No salpingectomy
Number of subjects: 2800
Study 28729302 — intervention group
Group type: EXPERIMENTAL
Intervention: Vosaroxin 70 mg/m2 on days 1 and 4 with decitabine 20 mg/m2 on days 1-5 every 4-6 weeks for up to seven cycles
Number of subjects: 65
Study 28729302 — intervention group
Group type: EXPERIMENTAL
Intervention: Vosaroxin 70 mg/m2
Number of subjects: 65
Study 28729302 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal residual disease-negative status by multiparametric flow-cytometry at response (± 3 months)
Number of subjects: 65
Study 23688877 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrysof SN6AT IOL (Group A)
Number of subjects: 72
Study 23688877 — intervention group
Group type: EXPERIMENTAL
Intervention: AT Torbi 709M IOL (Group B)
Number of subjects: 72
Study 23688877 — intervention group
Group type: COMPARATOR
Intervention: Both Groups
Number of subjects: 72
Study 21843688 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate insertion (within 10 min of placenta delivery)
Number of subjects: 46
Study 21843688 — intervention group
Group type: EXPERIMENTAL
Intervention: Early insertion (10 min to 48 h postpartum)
Number of subjects: 46
Study 21843688 — intervention group
Group type: COMPARATOR
Intervention: Interval insertion (≥6 weeks postpartum)
Number of subjects: 46
Study 19250118 — intervention group
Group type: EXPERIMENTAL
Intervention: Central sleep apnea (CSA)
Number of subjects: 129
Study 19250118 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA)
Number of subjects: 129
Study 19250118 — intervention group
Group type: COMPARATOR
Intervention: No sleep apnea
Number of subjects: 129
Study 19250118 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of CSA and OSA
Number of subjects: 129
Study 17259188 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid diagnostic test (RDT)
Number of subjects: 2416
Study 17259188 — intervention group
Group type: COMPARATOR
Intervention: Routine microscopy
Number of subjects: 2416
Study 17259188 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative test by any method
Number of subjects: 2416
Study 17259188 — intervention group
Group type: EXPERIMENTAL
Intervention: Children aged under 5 with negative rapid diagnostic tests
Number of subjects: 2416
Study 15493565 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human follicle-stimulating hormone (rFSH)
Number of subjects: 241
Study 15493565 — intervention group
Group type: COMPARATOR
Intervention: highly purified urinary human FSH (uFSH)
Number of subjects: 241
Study 11406840 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed test for overall treatment effect
Number of subjects: 0
Study 11406840 — intervention group
Group type: COMPARATOR
Intervention: Commonly used tests in fixed effects model
Number of subjects: 0
Study 11406840 — intervention group
Group type: COMPARATOR
Intervention: Commonly used tests in random effects model
Number of subjects: 0
Study 9255748 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized 17 beta‐estradiol/oral sequential dydrogesterone
Number of subjects: 85
Study 9255748 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐estradiol/oral sequential dydrogesterone
Number of subjects: 85
Study 9255748 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tibolone
Number of subjects: 85
Study 9255748 — intervention group
Group type: COMPARATOR
Intervention: No hormone replacement therapy
Number of subjects: 85
Study 8291388 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated sufentanil-midazolam infusion
Number of subjects: 20
Study 8291388 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative analgesia with intravenous increments of morphine and midazolam
Number of subjects: 20
Study 2872429 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ritodrine hydrochloride
Number of subjects: 106
Study 2872429 — intervention group
Group type: COMPARATOR
Intervention: No tocolytic treatment (Control)
Number of subjects: 106
Study 30192782 — intervention group
Group type: EXPERIMENTAL
Intervention: GR-MD-02 (8 mg.kg-1 via IV infusion, biweekly for 16 weeks)
Number of subjects: 30
Study 30192782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27100898 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alcohol (0.02 g/100 ml blood alcohol concentration)
Number of subjects: 0
Study 27100898 — intervention group
Group type: COMPARATOR
Intervention: Placebo (alcohol-free, wine-flavored beverage)
Number of subjects: 0
Study 27100898 — intervention group
Group type: COMPARATOR
Intervention: Control group (informed about non-alcoholic beverage)
Number of subjects: 0
Study 24583546 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright locomotion replacement training (LRT)
Number of subjects: 10
Study 24583546 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet upright standing (STA)
Number of subjects: 10
Study 24583546 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 10
Study 22437449 — intervention group
Group type: COMPARATOR
Intervention: Lacosamide 50 mg single dose
Number of subjects: 48
Study 22437449 — intervention group
Group type: COMPARATOR
Intervention: Lacosamide 100 mg twice daily
Number of subjects: 48
Study 22437449 — intervention group
Group type: COMPARATOR
Intervention: Lacosamide 200 mg twice daily
Number of subjects: 48
Study 22437449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 20464647 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium (80 microg) in the morning
Number of subjects: 21
Study 20464647 — intervention group
Group type: COMPARATOR
Intervention: Placebo in the morning
Number of subjects: 21
Study 20464647 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium (80 microg) in the evening
Number of subjects: 21
Study 20464647 — intervention group
Group type: COMPARATOR
Intervention: Placebo in the evening
Number of subjects: 21
Study 18367682 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Production Therapy (VP)
Number of subjects: 62
Study 18367682 — intervention group
Group type: COMPARATOR
Intervention: Vocal Hygiene Education (VHE)
Number of subjects: 62
Study 18367682 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Production Therapy (VP) with self-study
Number of subjects: 62
Study 18367682 — intervention group
Group type: COMPARATOR
Intervention: Vocal Hygiene Education (VHE) with self-study
Number of subjects: 62
Study 15726579 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil (2-16 mg)
Number of subjects: 10
Study 15726579 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil (16 mg)
Number of subjects: 10
Study 15726579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12457375 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 71
Study 12457375 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide
Number of subjects: 71
Study 10517737 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (Ang II) infusion
Number of subjects: 20
Study 10517737 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (inhibitor of Ang II AT1 receptor)
Number of subjects: 20
Study 10517737 — intervention group
Group type: COMPARATOR
Intervention: Losartan (50 mg UID)
Number of subjects: 20
Study 10517737 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg UID)
Number of subjects: 20
Study 10517737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7861022 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine monotherapy
Number of subjects: 0
Study 7861022 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine with >200 CD4 cells/mm3
Number of subjects: 0
Study 7861022 — intervention group
Group type: EXPERIMENTAL
Intervention: Zalcitabine added to zidovudine in zidovudine-experienced patients
Number of subjects: 0
Study 7861022 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to didanosine in zidovudine-experienced patients
Number of subjects: 0
Study 7861022 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine administered to women after the first trimester
Number of subjects: 0
Study 7861022 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy in zidovudine-experienced patients with <50 CD4 cells/mm3
Number of subjects: 0
Study 1873448 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A, 25,000 IU; beta-carotene, 50 mg; vitamin E, 800 IU; selenium, 400 micrograms (administered daily)
Number of subjects: 350
Study 1873448 — intervention group
Group type: COMPARATOR
Intervention: Placebos (administered daily)
Number of subjects: 350
Study 6874485 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (20 inhalations to total lung capacity, held for 10 s each day for 6 weeks)
Number of subjects: 16
Study 6874485 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 16
Study 6874485 — intervention group
Group type: COMPARATOR
Intervention: Control group (nontraining)
Number of subjects: 16
Study 31915235 — intervention group
Group type: EXPERIMENTAL
Intervention: VA-dual therapy (vonoprazan 20 mg + amoxicillin 750 mg twice/day)
Number of subjects: 335
Study 31915235 — intervention group
Group type: COMPARATOR
Intervention: VAC-triple therapy (vonoprazan 20 mg + amoxicillin 750 mg + clarithromycin 200 mg twice/day)
Number of subjects: 335
Study 31915235 — intervention group
Group type: EXPERIMENTAL
Intervention: VA-dual therapy
Number of subjects: 335
Study 31915235 — intervention group
Group type: COMPARATOR
Intervention: VAC-triple therapy
Number of subjects: 335
Study 31915235 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 335
Study 31034597 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologists' predictions
Number of subjects: 263
Study 31034597 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' predictions
Number of subjects: 263
Study 31034597 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers' predictions
Number of subjects: 263
Study 28937899 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone gas
Number of subjects: 80
Study 28937899 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide (Ca(OH)2) base material
Number of subjects: 80
Study 26800893 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheongsangbangpoong-tang (CBT)
Number of subjects: 56
Study 24390150 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant! Online
Number of subjects: 303
Study 24390150 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutch breast cancer guideline 2012
Number of subjects: 303
Study 23031366 — intervention group
Group type: EXPERIMENTAL
Intervention: Alglucosidase alfa 20mg/kg biweekly for 26 weeks
Number of subjects: 0
Study 19261038 — intervention group
Group type: EXPERIMENTAL
Intervention: Image integration-guided ablation (CartoMerge TM)
Number of subjects: 290
Study 19261038 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiofrequency catheter ablation
Number of subjects: 290
Study 17453967 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 days of G-CSF administration
Number of subjects: 24
Study 17453967 — intervention group
Group type: COMPARATOR
Intervention: 6 days of G-CSF administration
Number of subjects: 24
Study 18084873 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 50 mg/day
Number of subjects: 105
Study 18084873 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine 20 mg/day
Number of subjects: 105
Study 11680522 — intervention group
Group type: EXPERIMENTAL
Intervention: VAX-D
Number of subjects: 0
Study 11680522 — intervention group
Group type: COMPARATOR
Intervention: TENS
Number of subjects: 0
Study 9838263 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 14
Study 9838263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8081180 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.5 mg
Number of subjects: 20
Study 8081180 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 20
Study 8081180 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1.5 mg
Number of subjects: 20
Study 8081180 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 20
Study 8081180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8081180 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (all doses)
Number of subjects: 20
Study 2692145 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged antithrombotic treatment with anticoagulants or antiplatelet drugs (50 mg aspirin + 400 mg dipyridamole daily)
Number of subjects: 649
Study 2692145 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment after 3 months of active therapy
Number of subjects: 649
Study 1096538 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam 4.8 g/day for 3 days
Number of subjects: 18
Study 1096538 — intervention group
Group type: COMPARATOR
Intervention: Control (no piracetam)
Number of subjects: 18
Study 31818787 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg/day
Number of subjects: 1811
Study 31818787 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg/day
Number of subjects: 1811
Study 31818787 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 5 mg/day
Number of subjects: 1811
Study 31818787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1811
Study 29482372 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochures with a short personal narrative
Number of subjects: 1135
Study 29482372 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochures without a personal narrative
Number of subjects: 1135
Study 29482372 — intervention group
Group type: COMPARATOR
Intervention: No-exposure control arm
Number of subjects: 1135
Study 28770409 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger Point (TP) therapy alone
Number of subjects: 0
Study 28770409 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger Point (TP) therapy combined with Lymphatic Drainage (LD)
Number of subjects: 0
Study 28770409 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 0
Study 25998450 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate 100 mg given four times over 10 days
Number of subjects: 64
Study 25998450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 23395302 — intervention group
Group type: EXPERIMENTAL
Intervention: PCC Coding System (PCCCS)
Number of subjects: 30
Study 21842171 — intervention group
Group type: EXPERIMENTAL
Intervention: sugammadex (2 mg/kg)
Number of subjects: 0